secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K/A
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0000899923-25-000109
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics Q3 revenue $205.7M (-4% YoY); adjusted EPS $0.00; reaffirms FY2025 guidance
--------------------------------------------------------------------------------

- Q3 revenue $205.7M, down 4% YoY; flat excluding $8.1M headwinds (UNH GeneSight loss, EndoPredict divestiture).
- GAAP net loss $27.4M ($0.29 loss); adjusted EPS $0.00; adjusted EBITDA $10.3M.
- Hereditary cancer testing volume +11% YoY; GeneSight revenue -19% YoY due to UnitedHealthcare coverage change.
- Entered strategic CDx collaboration with SOPHiA GENETICS for liquid biopsy companion diagnostics.
- Reiterates FY2025 revenue $818-828M, gross margin 69.5-70%, adjusted EBITDA $27-33M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992325000109/0000899923-25-000109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992325000109/mygn-20251103.htm
  HTML page:      https://secwatch.observer/filing/0000899923-25-000109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer